Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. - Wikidata - wikimedia - TriplyDB

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

http://www.wikidata.org/entity/Q34333145

about

Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma.Treatment of Hepatitis B: A Concise Review.Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?Patients with hematological malignancies and serological signs of prior resolved hepatitis B.Update on entecavir in the management of severe forms of Hepatitis B.Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma.Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case.Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.

P2860

Q26752690-01316949-1B2E-4D35-AA27-D377347F7009 Q27000080-96166769-8981-426E-B29E-F1AFDB312C46 Q33564294-3E27968B-473B-449F-BC43-DD50D3861DD0 Q34397738-7655AA0C-6340-49E7-9EF4-C884479A074E Q36225933-B44DC38A-7C0E-4961-B163-236C3580CF65 Q37620340-F193D89E-EBDC-41F6-B288-26B237891749 Q37912229-295F0ADE-8536-486F-9497-270B672EF418 Q37958234-F2E5715A-010D-4BB0-A444-BE230E744D2C Q37999022-00452F51-6009-49D1-B592-7BF129EA3225 Q38201711-BCD78028-D9E7-4A18-B71C-3C3B84EAA2E1 Q43248230-0E206413-93D6-45B5-AEEC-A0CBC1D8FEDC Q44688947-16BF272A-453B-438A-BA0B-06F6EFFAFE04 Q45326378-FB07AAB4-3EAC-4FED-9D5D-E3594B87C0F2

P2860

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

http://www.wikidata.org/entity/Q34333145

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@ast

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@en

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@nl

type

label

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@ast

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@en

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@nl

prefLabel

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@ast

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@en

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@nl

P1433

Q34333145-B7473227-945E-4B55-94A0-FCEFDD07A2AF

P1476

Q34333145-13C09E90-13A3-45FF-9737-036D69141A1F

P2093

Q34333145-35F6971A-EFF3-4FA7-935D-2A9367DDEFAA

Q34333145-819AE117-9FAF-4191-9C95-2B2FBF725C23

Q34333145-9E9E5374-F08A-4BB0-9606-E3B35BBA42AA

Q34333145-D01EF3DD-B5B0-4D1F-9970-523867DFD32F

P2860

Q34333145-0A700401-A7BD-4741-9C1D-263E6F6E7B23

Q34333145-0E288AD0-28B4-48F8-970B-910C984843D6

Q34333145-214DB2DA-5987-4FDF-806A-8F84D4DC255E

Q34333145-2B147EF0-6C02-40BB-9DD5-4ECC8D789E7C

Q34333145-482155EC-67C2-434A-976D-37FBC4E41E4B

Q34333145-4FEA7AB2-5B9C-434B-AAA6-95845508F218

Q34333145-5B497707-3F01-478C-9E62-67150367269E

Q34333145-5B98F888-5163-448C-BE17-E901828B19DB

Q34333145-6C3673B6-593F-4101-BDDB-9D694FA6968D

Q34333145-6D7BE4B5-DBD9-4F45-8C11-C65EBBD472A7

P304

Q34333145-F9873DA2-2999-4FDD-A8F3-58E04DE44C3B

P31

Q34333145-CFD2725A-15F6-4A73-AF2B-28DC0A97833C

P356

Q34333145-E24CEE6C-9EBD-4908-A36A-C2513CF2155F

P407

Q34333145-06F9DBB5-B219-4BEB-8590-B25EEC23CB3A

P433

Q34333145-3E4E221A-2FDE-4ED7-BEA0-9E744F9D3E28

P478

Q34333145-7117642B-B8E4-4D44-897F-292EB5E5F7C2

P577

Q34333145-8935C2D2-FD69-4382-8A49-D2C11BEF189D

P5875

Q34333145-BFB30608-2165-4397-A62D-408C9189DD5D

P698

Q34333145-340BE884-41C6-4E97-A869-C02069F251C1

P921

Q34333145-5CAE6718-4686-4B1F-A70C-694BED4D7317

P932

Q34333145-1E0EA7BB-5A56-4903-8CDD-E7AD053A5824

P356

WJG.V16.I43.5447

P1433

World Journal of Gastroenterology

P1476

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

@en

P2093

Christoph Eisenbach

http://www.w3.org/2001/XMLSchema#string

Paul Schnitzler

http://www.w3.org/2001/XMLSchema#string

Sylvia Brost

http://www.w3.org/2001/XMLSchema#string

Wolfgang Stremmel

http://www.w3.org/2001/XMLSchema#string

P2860

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.

Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia.

Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir.

Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.

P304

5447-5451

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V16.I43.5447

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276054152

http://www.w3.org/2001/XMLSchema#string

P698

21086562

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

2988237

http://www.w3.org/2001/XMLSchema#string